Should I Buy NRXP? NRXP 2026 Analysis

Should You Buy NRX Pharmaceuticals Inc (NRXP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.910

1 Day change

13.69%

52 Week Range

3.840

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price is in a strong downtrend and still showing downside momentum.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Options positioning is very call-skewed (bullish sentiment), but that has not yet translated into price strength.
No fresh news/catalysts this week; the next meaningful fundamental catalyst appears to be 2026 FDA action-date driven, which doesn’t help near-term timing.
With the stock below key support (S1) and MACD still worsening, the higher-probability path is continued chop/down before a durable reversal.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend across timeframes.
Momentum: MACD histogram -0.0379 and negatively expanding → downside momentum is still building, not stabilizing.
Overbought/oversold: RSI_6 19.12 = deeply oversold; a short bounce is possible, but oversold can persist in a downtrend.
Key levels:
- Pivot: 2.048 (well above current price, acting as overhead resistance)
- Support: S1 1.819 (already broken), next S2 1.677 (near-term downside magnet)
- Resistance: R1 2.277, R2 2.419 (far overhead)
Pattern-based odds (given): estimated +0.71% next day, +3.34% next week, +10.89% next month—positive skew, but not enough to override the currently bearish tape.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Extremely call-heavy open interest (Put/Call OI 0.08) and call-heavy volume (Put/Call volume 0.09) → bullish/leveraged upside bias.
Activity: Today’s volume 139 vs 30D avg (shown) indicates elevated relative activity (volume today vs avg 80.35 as provided).
Volatility: 30D IV 107.79% vs HV 67.02% (options pricing in big moves), yet IV percentile ~4.38 / IV rank ~4.41 implies IV is low relative to its own recent history—options are comparatively “cheaper” than usual for NRXP.
Takeaway: Options market leans bullish, but price action remains decisively bearish; sentiment alone is not a reliable buy trigger here.

Technical Summary

Sell

Buy

Positive Catalysts

- Potential 2026 FDA action dates for NRX-100 and NRX-101 (per the lone analyst note) could become major upside catalysts as milestones approach.
- Deeply oversold RSI increases odds of a short-term relief bounce.
- Options market is aggressively call-skewed, suggesting traders are positioned for upside moves.

Neutral/Negative Catalysts

- Strong downtrend + worsening MACD: current technical structure favors continued weakness/failed bounces.
- No news in the recent week, reducing the chance of an immediate event-driven reversal.
- Trading flows: Hedge funds neutral and insiders neutral → no supportive accumulation signal.
- Current price is below S1 support (1.819), with next support at 1.677 close enough to be tested if selling persists.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $242K, flat YoY (0.00%) → minimal top-line traction.
Net income: - $5.89M (improved 262.91% YoY per provided figure, but still materially loss-making).
EPS: -0.26, improved 73.33% YoY but remains negative.
Gross margin: 49.17% (flat YoY) → margin structure okay, but scale is the issue.
Bottom line: financials show loss improvement, but no meaningful growth yet—hard to support an impatient “buy now” without a clear near-term catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Latest/only provided update (2026-01-02): Ascendiant reiterated Buy and raised PT to $48 from $47 following the Q3 report.
Trend: positive (slight PT increase; rating maintained Buy), but based on 2026 milestone expectations rather than near-term fundamentals.
Wall Street pro view (pros): large upside optionality tied to NRX-100/NRX-101 and anticipated FDA events.
Wall Street con view (cons): timing risk (key events are later), current price trend is bearish, and fundamentals show limited revenue scale today.
Influential/political activity: No recent congress trading data available; no notable insider trend flagged (insiders neutral).

3 Analyst Rating

Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is 37.67 USD with a low forecast of 25 USD and a high forecast of 48 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.680

Low

Averages

37.67

High

Current: 1.680

Low

Averages

37.67

High

Ascendiant

Buy

maintain

$47 -> $48

AI Analysis

2026-01-02

Reason

Ascendiant

Price Target

$47 -> $48

AI Analysis

2026-01-02

maintain

Buy

Reason

Ascendiant raised the firm's price target on NRx Pharmaceuticals to $48 from $47 and keeps a Buy rating on the shares following the Q3 report in November. The firm sees "major opportunities" for NRX-100 and NRX-101, which should both have FDA action dates in 2026. The firm sees these news events driving NRx shares in 2026.

H.C. Wainwright

initiated

$40

2025-09-08

Reason

H.C. Wainwright

Price Target

$40

2025-09-08

initiated

Reason

H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a Buy rating and $40 price target. the company is combining novel therapeutics with integrated mental health care delivery to address acute suicidality in depression, the analyst tells investors in a research note. The firm believes NRx is positioned to become a leader in high-isk mood disorders and remains \"significantly undervalued\" at current share levels.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRXP

Unlock Now

NRXP Should I Buy

NRXP Should I Buy

Should You Buy NRX Pharmaceuticals Inc (NRXP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch